Achromatopsia – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of achromatopsia (ACHM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of ACHM for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s ACHM forecast will answer the following questions:
- Of all people with ACHM, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ACHM over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts four ACHM patient populations, as follows:
- Diagnosed prevalent cases of ACHM.
- Diagnosed prevalent cases of ACHM by CNGA3+ mutation.
- Diagnosed prevalent cases of ACHM by CNGB3+ mutation.
- Diagnosed prevalent cases of ACHM by other/unknown status.
Note: Coverage may vary by country.
